Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition
Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMENDMENT NO. 1 TO THE COMMON STOCK SALES AGREEMENT August 6, 2026 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: This Amendment No. 1 to the Sales Agreement, dated as of August 6, 2026, is entered into by and between Relay
How this was made
The 30-second read
Why it matters
Traders can update expectations for (1) funding runway, (2) the timing of the planned 1L endocrine-sensitive Phase 3 trial, and (3) near-term narrative momentum from early clinical readouts and ongoing Phase 3 execution.
Market read
The filing combines a fresh capital position update with specific clinical timeline guidance and early efficacy/tolerability signals, which can drive development-stage biotech repricing.
What to watch
The filing also shows higher R&D and a large ongoing net loss; dilution risk and trial execution/regulatory feedback timing could cap upside despite the cash runway.
Background
This SEC 8-K reports Relay Therapeutics’ Q2 2026 financial results and provides corporate and clinical development updates across its lead zovegalisib program and earlier-stage pipeline.
Ticker impact
Relay reported Q2 2026 results and disclosed zovegalisib clinical progress, including a planned 1L Phase 3 start in early 2027 and cash runway into 2029.
Near-term volatility likely driven by the combination of cash runway into 2029 and incremental clinical readouts/timeline clarity; directionally supportive if investors view the triplet and vascular-anomalies data as de-risking.
The filing is a fresh 8-K with multiple concrete updates (cash $910.9M, offering proceeds, Phase 3 initiation timing, and early response/tolerability figures). However, it is not an approval or definitive regulatory outcome, so magnitude of repricing is uncertain.
Market effects
Reinforces investor appetite for PI3Kα allosteric/mutant-selective oncology programs and combination regimens, potentially improving sentiment for similar precision oncology developers.
Limited direct regional spillover; primarily affects US small-cap biotech sentiment.
Modest global relevance given the US-listed issuer and conference presentation, not a cross-border regulatory decision.
Counterpoint
Early Phase 1/2 vascular-anomalies response and 3L triplet ORR may not translate into Phase 3 efficacy, so the market could fade the catalyst if endpoints are not validated.
Key entities
- companyRelay Therapeutics, Inc.
Nasdaq-listed clinical-stage precision medicine company; subject of the 8-K with Q2 results and zovegalisib program updates.
- drug_programzovegalisib
Lead mutant-selective PI3Kα inhibitor; updated across 1L/2L breast cancer and vascular anomalies.
- drug_programatirmociclib
CDK4/6 inhibitor used in the proposed zovegalisib triplet regimen; Pfizer to supply for the experimental arm.
- drug_programRLY-8161
NRAS-selective inhibitor with ongoing Phase 1/2 trial execution.
- counterpartyPfizer
Agreed to supply atirmociclib (and palbociclib for control) for the planned 1L study; Relay retains global rights for zovegalisib.
